Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation
Top Cited Papers
Open Access
- 31 October 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Abstract
The comparative effectiveness of finerenone and spironolactone in chronic kidney disease (CKD) with type 2 diabetes (T2D) remains unclear. Here we show, using a target trial emulation on global real-world data from TriNetX, outcomes among 2268 propensity score–matched adults with CKD (eGFR 15–60 mL/min/1.73 m²) and T2D who initiated finerenone or spironolactone between July 2021 and September 2024. Over a median follow-up of 1.3 years, finerenone is associated with lower risks of major adverse cardiovascular events (adjust hazard ratio [aHR], 0.74; 95% CI, 0.58–0.94), major adverse kidney events (aHR, 0.47; 95% CI, 0.33–0.67), all-cause mortality (aHR, 0.31; 95% CI, 0.21–0.45), and hyperkalemia (17.2% vs. 26.4%; P < 0.001) compared with spironolactone. These findings suggest potential benefits of finerenone over spironolactone in reducing mortality and cardiorenal risk among patients with CKD and T2D.Keywords
Funding Information
- Mrs. Hsiu-Chin Lee Kidney Research Foundation
This publication has 54 references indexed in Scilit:
- Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney DiseaseJAMA Internal Medicine, 2025
- Cost-Effectiveness Analysis of Finerenone for Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes from Japanese Payer PerspectiveAdvances in Therapy, 2024
- Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 DiabetesJAMA Network Open, 2024
- Cost-effectiveness of Finerenone in Addition to Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in ChinaAdvances in Therapy, 2024
- Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney DiseaseJAMA Network Open, 2024
- Target Trial EmulationJAMA, 2022
- Comparison of a Target Trial Emulation Framework vs Cox Regression to Estimate the Association of Corticosteroids With COVID-19 MortalityJAMA Network Open, 2022
- Association of Spironolactone Use With Risk of CancerJAMA Dermatology, 2022
- Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data from 9222 Chronic Heart Failure Patients of the ESC-HFA-EORP Heart Failure Long-Term RegistryEuropean Journal of Heart Failure, 2020
- World Medical Association Declaration of HelsinkiJAMA, 2013